773 related articles for article (PubMed ID: 10197959)
21. Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes.
Blanco FJ; Guitian R; Moreno J; de Toro FJ; Galdo F
J Rheumatol; 1999 Jun; 26(6):1366-73. PubMed ID: 10381057
[TBL] [Abstract][Full Text] [Related]
22. 3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)(2-pyridyl) phenyl ketone as a potent and orally active cyclooxygenase-2 selective inhibitor: synthesis and biological evaluation.
Khanapure SP; Augustyniak ME; Earl RA; Garvey DS; Letts LG; Martino AM; Murty MG; Schwalb DJ; Shumway MJ; Trocha AM; Young DV; Zemtseva IS; Janero DR
J Med Chem; 2005 Jun; 48(11):3930-4. PubMed ID: 15916445
[TBL] [Abstract][Full Text] [Related]
23. Discovery of a novel COX-2 inhibitor as an orally potent anti-pyretic and anti-inflammatory drug: design, synthesis, and structure-activity relationship.
Hayashi S; Sumi Y; Ueno N; Murase A; Takada J
Biochem Pharmacol; 2011 Oct; 82(7):755-68. PubMed ID: 21741371
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and anti-inflammatory activity of alkyl/arylidene-2-aminobenzothiazoles and 1-benzothiazol-2-yl-3-chloro-4-substituted-azetidin-2-ones.
Khedekar PB; Bahekar RH; Chopade RS; Umathe SN; Rao AR; Bhusari KP
Arzneimittelforschung; 2003; 53(9):640-7. PubMed ID: 14558438
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases.
Rao PN; Chen QH; Knaus EE
J Med Chem; 2006 Mar; 49(5):1668-83. PubMed ID: 16509583
[TBL] [Abstract][Full Text] [Related]
26. Ulcerogenic influence of selective cyclooxygenase-2 inhibitors in the rat stomach with adjuvant-induced arthritis.
Kato S; Ogawa Y; Kanatsu K; Okayama M; Watanabe T; Arakawa T; Takeuchi K
J Pharmacol Exp Ther; 2002 Nov; 303(2):503-9. PubMed ID: 12388629
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of COX-1/COX-2 selectivity and potency of a new class of COX-2 inhibitors.
Gierse J; Nickols M; Leahy K; Warner J; Zhang Y; Cortes-Burgos L; Carter J; Seibert K; Masferrer J
Eur J Pharmacol; 2008 Jun; 588(1):93-8. PubMed ID: 18457826
[TBL] [Abstract][Full Text] [Related]
28. Investigations of new pyridazinone derivatives for the synthesis of potent analgesic and anti-inflammatory compounds with cyclooxygenase inhibitory activity.
Okçelik B; Unlü S; Banoglu E; Küpeli E; Yeşilada E; Sahin MF
Arch Pharm (Weinheim); 2003 Sep; 336(9):406-12. PubMed ID: 14528488
[TBL] [Abstract][Full Text] [Related]
29. Cyclo-oxygenase isozymes in mucosal ulcergenic and functional responses following barrier disruption in rat stomachs.
Hirata T; Ukawa H; Yamakuni H; Kato S; Takeuchi K
Br J Pharmacol; 1997 Oct; 122(3):447-54. PubMed ID: 9351500
[TBL] [Abstract][Full Text] [Related]
30. Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.
Gierse JK; Zhang Y; Hood WF; Walker MC; Trigg JS; Maziasz TJ; Koboldt CM; Muhammad JL; Zweifel BS; Masferrer JL; Isakson PC; Seibert K
J Pharmacol Exp Ther; 2005 Mar; 312(3):1206-12. PubMed ID: 15494548
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and structure-activity relationship of novel, highly potent metharyl and methcycloalkyl cyclooxygenase-2 (COX-2) selective inhibitors.
Khanapure SP; Garvey DS; Young DV; Ezawa M; Earl RA; Gaston RD; Fang X; Murty M; Martino A; Shumway M; Trocha M; Marek P; Tam SW; Janero DR; Letts LG
J Med Chem; 2003 Dec; 46(25):5484-504. PubMed ID: 14640557
[TBL] [Abstract][Full Text] [Related]
32. Roles of endogenous prostaglandins and cyclooxygenase izoenzymes in mucosal defense of inflamed rat stomach.
Takeeda M; Hayashi Y; Yamato M; Murakami M; Takeuchi K
J Physiol Pharmacol; 2004 Mar; 55(1 Pt 2):193-205. PubMed ID: 15082878
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological profile of celecoxib, a specific cyclooxygenase-2 inhibitor.
Yoshino T; Kimoto A; Kobayashi S; Noguchi M; Fukunaga M; Hayashi A; Miyata K; Sasamata M
Arzneimittelforschung; 2005; 55(7):394-402. PubMed ID: 16080279
[TBL] [Abstract][Full Text] [Related]
34. Relationship between cyclooxygenase 1 and 2 selective inhibitors and fetal development when administered to rats and rabbits during the sensitive periods for heart development and midline closure.
Cappon GD; Cook JC; Hurtt ME
Birth Defects Res B Dev Reprod Toxicol; 2003 Feb; 68(1):47-56. PubMed ID: 12852483
[TBL] [Abstract][Full Text] [Related]
35. Rofecoxib produces intestinal but not gastric damage in the presence of a low dose of indomethacin in rats.
Yokota A; Taniguchi M; Takahira Y; Tanaka A; Takeuchi K
J Pharmacol Exp Ther; 2005 Jul; 314(1):302-9. PubMed ID: 15831440
[TBL] [Abstract][Full Text] [Related]
36. Diarylspiro[2.4]heptenes as orally active, highly selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationships.
Huang HC; Li JJ; Garland DJ; Chamberlain TS; Reinhard EJ; Manning RE; Seibert K; Koboldt CM; Gregory SA; Anderson GD; Veenhuizen AW; Zhang Y; Perkins WE; Burton EG; Cogburn JN; Isakson PC; Reitz DB
J Med Chem; 1996 Jan; 39(1):253-66. PubMed ID: 8568815
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).
Penning TD; Talley JJ; Bertenshaw SR; Carter JS; Collins PW; Docter S; Graneto MJ; Lee LF; Malecha JW; Miyashiro JM; Rogers RS; Rogier DJ; Yu SS; AndersonGD ; Burton EG; Cogburn JN; Gregory SA; Koboldt CM; Perkins WE; Seibert K; Veenhuizen AW; Zhang YY; Isakson PC
J Med Chem; 1997 Apr; 40(9):1347-65. PubMed ID: 9135032
[TBL] [Abstract][Full Text] [Related]
38. Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation.
Wallace JL; Zamuner SR; McKnight W; Dicay M; Mencarelli A; del Soldato P; Fiorucci S
Am J Physiol Gastrointest Liver Physiol; 2004 Jan; 286(1):G76-81. PubMed ID: 14665439
[TBL] [Abstract][Full Text] [Related]
39. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
Zweifel BS; Davis TW; Ornberg RL; Masferrer JL
Cancer Res; 2002 Nov; 62(22):6706-11. PubMed ID: 12438270
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents.
Selvam C; Jachak SM; Thilagavathi R; Chakraborti AK
Bioorg Med Chem Lett; 2005 Apr; 15(7):1793-7. PubMed ID: 15780608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
